Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Feb 28:rs.3.rs-2574215.
doi: 10.21203/rs.3.rs-2574215/v1.

Bumetanide Exposure Association with Alzheimer's Disease Risk

Anna Graber-Naidich  1 , Justin Lee  1 , Kyan Younes  1 , Michael D Greicius  1 , Yann Le Guen  1 , Zihuai He  1
Affiliations

Bumetanide Exposure Association with Alzheimer's Disease Risk

Anna Graber-Naidich et al. Res Sq. .

Update in

Abstract

Background: To investigate whether exposure history to two common loop diuretics affects the risk of developing Alzheimer's disease (AD) after accounting for socioeconomic status and congestive heart failure.

Methods: Individuals exposed to bumetanide or furosemide were identified in the Stanford University electronic health record using the deidentified Observational Medical Outcomes Partnership platform. We matched the AD case cohort to a control cohort (1:20 case:control) on gender, race, ethnicity, hypertension and controlled for variables that could potentially be collinear with bumetanide exposure and/or AD diagnosis. Among individuals older than 65 years, 5,839 AD cases and 116,103 matched controls were included. A total of 1,759 patients (54 cases, 1,705 controls) were exposed to bumetanide.

Results: After adjusting for socioeconomic status and other confounders, bumetanide exposure was significantly associated with reduced AD risk (odds ratio = 0.50; 95% confidence interval, 0.37-0.68; p = 9.9×10-6), while the most common loop diuretics, furosemide, was not associated with AD risk.

Conclusion: Our study replicates in an independent sample that history of bumetanide exposure is associated with reduced risk of AD and emphasizes that this association is not confounded by difference in socioeconomic status, which was an important caveat given the cost difference between bumetanide and furosemide.

Keywords: Alzheimer’s disease; bumetanide; electronic health record informatics; furosemide.

PubMed Disclaimer

Conflict of interest statement

Competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

References

    1. Shah NH, Milstein A, Bagley PhD SC. Making Machine Learning Models Clinically Useful. JAMA. United States; 2019;322:1351–1352. - PubMed
    1. Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. The New England journal of medicine. United States; 2019;380:1347–1358. - PubMed
    1. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020–2060). Alzheimer’s and Dementia. 2021;17:1966–1975. - PMC - PubMed
    1. Taubes A, Nova P, Zalocusky KA, et al. APOE4 -related Alzheimer’ s disease. 2021;1. - PMC - PubMed
    1. Datta S, Posada J, Olson G, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. Epub 2020.

Publication types

LinkOut - more resources